• Earlier in August 2026, Pomerantz LLP announced an investigation into Calumet, Inc. after the company reported quarterly results showing weaker adjusted EBITDA in its Performance Brands segment and operational challenges, including downtime and delayed sustainable aviation fuel ramp-up at Montana Renewables.
• The combination of higher input costs, timing-related earnings pressure, and legal scrutiny has raised fresh questions about the resilience of Calumet’s multi-segment business model and its renewable fuels transition.
• We’ll now examine how the Montana Renewables downtime and delayed SAF ramp-up may reshape Calumet’s previously optimistic investment narrative.

The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Calumet Investment Narrative Recap

To own Calumet today, you have to believe its pivot toward renewables and higher value specialty products can eventually outweigh current losses and balance sheet strain. The latest report of weaker Performance Brands EBITDA and the Montana Renewables downtime directly pressure the key near term catalyst of a smooth SAF ramp-up, while also sharpening the biggest current risk around execution and cash flow consistency. The Pomerantz investigation adds another layer of short term uncertainty, though its ultimate impact is still unclear.

Against this backdrop, the August 7, 2026 earnings release is especially important. The quarter highlighted higher sales but a wider year to date net loss of US$412.9 million, plus the SAF ramp delay and downtime at Montana Renewables. For an investment case that leans heavily on MaxSAF 150 and improving renewables margins, these operational setbacks matter because they test the timing and reliability of the very cash flows many shareholders are counting on.

Yet, investors should also be aware that the real test may come if regulatory support for renewable fuels weakens just as Montana Renewables is trying to...

Calumet's narrative projects $5.3 billion revenue and $226.9 million earnings by 2029. This requires 8.6% yearly revenue growth and a $415.7 million earnings increase from -$188.8 million today.

Uncover how Calumet's forecasts yield a $38.80 fair value, a 15% downside to its current price.

Exploring Other Perspectives

Compared with the consensus story, the most cautious analysts already expected only about US$4.2 billion of revenue and US$142.4 million of earnings by 2029, so this setback could push their more skeptical view on regulatory risk and Montana Renewables even further, reminding you that expectations differ widely and are worth comparing side by side.

Explore 2 other fair value estimates on Calumet - why the stock might be worth as much as 31% more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Calumet research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Calumet research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Calumet's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

• Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.